MedTrace Logo

Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV

NCT00286832 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2011-07-06

No results posted yet for this study

Summary

Early identification of refractory lymphoma patients provides a basis for stratification between responders to standard approaches and non-responders who may benefit from an early change to an alternative treatment strategy.Metabolic or molecular imaging with fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has emerged as a powerful imaging modality for diagnosis, staging, and therapy monitoring of a variety of cancers. The primary hypothesis of the present study is that early response can be pinpointed by PET reflecting both tumor burden and activity, as a surrogate for final outcome. An increasing number of studies have suggested the potential role of 18F-FDG PET in the staging and monitoring of lymphomas. The optimal timing of PET scans and the potential role of quantitative PET using SUV to assess response to chemotherapy remain to be defined. Confirmation of very early 18F-FDG-PET as a significant predictor of treatment response in a homogenous group of aggressive lymphoma patients would potentially change the prognosis of the patient by allowing earlier use of alternative therapies and discontinuation of therapy that will not lead to a significant tumour response.

Conditions

  • Diffuse Large-Cell Lymphoma

Interventions

PROCEDURE

PET scan

One extra PET scan after 1 cycle of treatment.

Sponsors & Collaborators

  • Nordic Lymphoma Group

    collaborator NETWORK

  • Copenhagen University Hospital at Herlev

    lead OTHER

Principal Investigators

  • Lars M Pedersen, MD · Nordic Lymphoma Group (Large Cell Group)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00286832 on ClinicalTrials.gov